HK1223657A1 - 與wnt途徑抑制劑有關的預測性生物標記物的鑒別 - Google Patents

與wnt途徑抑制劑有關的預測性生物標記物的鑒別 Download PDF

Info

Publication number
HK1223657A1
HK1223657A1 HK16111927.7A HK16111927A HK1223657A1 HK 1223657 A1 HK1223657 A1 HK 1223657A1 HK 16111927 A HK16111927 A HK 16111927A HK 1223657 A1 HK1223657 A1 HK 1223657A1
Authority
HK
Hong Kong
Prior art keywords
seq
tumor
biomarker
antibody
pathway inhibitor
Prior art date
Application number
HK16111927.7A
Other languages
English (en)
Chinese (zh)
Inventor
Ann M. Kapoun
Chun Zhang
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Publication of HK1223657A1 publication Critical patent/HK1223657A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16111927.7A 2013-12-02 2014-12-02 與wnt途徑抑制劑有關的預測性生物標記物的鑒別 HK1223657A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361910663P 2013-12-02 2013-12-02
US61/910,663 2013-12-02
US201461975339P 2014-04-04 2014-04-04
US61/975,339 2014-04-04
PCT/US2014/068097 WO2015084808A1 (en) 2013-12-02 2014-12-02 Identification of predictive biomarkers associated with wnt pathway inhibitors

Publications (1)

Publication Number Publication Date
HK1223657A1 true HK1223657A1 (zh) 2017-08-04

Family

ID=53274023

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111927.7A HK1223657A1 (zh) 2013-12-02 2014-12-02 與wnt途徑抑制劑有關的預測性生物標記物的鑒別

Country Status (9)

Country Link
EP (1) EP3077546A4 (https=)
JP (1) JP2017501137A (https=)
CN (1) CN105829547A (https=)
AU (1) AU2014357354A1 (https=)
CA (1) CA2931975A1 (https=)
HK (1) HK1223657A1 (https=)
MX (1) MX2016007066A (https=)
TW (1) TW201610168A (https=)
WO (1) WO2015084808A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
WO2017023971A1 (en) * 2015-08-03 2017-02-09 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
CN106990245B (zh) * 2017-04-05 2018-07-31 东南大学 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110835372B (zh) * 2019-11-06 2020-12-01 上海健康医学院 一种靶向Frizzled7单克隆抗体及其制备方法与应用
JP7593584B2 (ja) * 2020-03-10 2024-12-03 学校法人杏林学園 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN115337400A (zh) * 2021-05-13 2022-11-15 中国科学院分子细胞科学卓越创新中心 诊断和治疗肿瘤的试剂及其用途
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
JPWO2023113013A1 (https=) * 2021-12-17 2023-06-22
WO2024189200A1 (en) * 2023-03-15 2024-09-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Cancer stratification and treatment

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1194549A2 (en) * 1999-07-02 2002-04-10 Chiron Corporation Human genes and gene expression products
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004032838A2 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
SG174100A1 (en) 2006-09-08 2011-09-29 Genentech Inc Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
EP2084296B1 (en) * 2006-09-29 2015-08-05 Agendia N.V. High-throughput diagnostic testing using arrays
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
CN103002911B (zh) * 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
WO2010101793A2 (en) * 2009-03-06 2010-09-10 University Of South Alabama Methods and compositions for the diagnosis, prognosis and treatment of cancer
CA2786745A1 (en) 2010-01-12 2011-07-21 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法

Also Published As

Publication number Publication date
AU2014357354A1 (en) 2016-06-09
TW201610168A (zh) 2016-03-16
EP3077546A4 (en) 2017-04-26
EP3077546A1 (en) 2016-10-12
JP2017501137A (ja) 2017-01-12
CA2931975A1 (en) 2015-06-11
WO2015084808A1 (en) 2015-06-11
WO2015084808A4 (en) 2015-08-13
CN105829547A (zh) 2016-08-03
MX2016007066A (es) 2016-09-08

Similar Documents

Publication Publication Date Title
HK1223657A1 (zh) 與wnt途徑抑制劑有關的預測性生物標記物的鑒別
RU2579897C2 (ru) Агенты, связывающие рецептор "frizzled", и их применение
CN102971337B (zh) 卷曲蛋白结合药剂及其应用
US8975375B2 (en) Identification of tumor-associated antigens for diagnosis and therapy
US20150132301A1 (en) Combination Therapy for Treatment of Cancer
EA032038B1 (ru) Rspo3-связывающие агенты и их применение
EP2523974A1 (en) Wnt-binding agents and uses thereof
KR20090111307A (ko) 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도
US20170023576A1 (en) Notch3 antibodies and uses thereof
CN105051215A (zh) 治疗胰腺癌的方法
US9168300B2 (en) MET-binding agents and uses thereof
AU2015227247A1 (en) Methods for treating cancer with Notch 1 antibodies
US20160304968A1 (en) Identification of Predictive Biomarkers Associated With WNT Pathway Inhibitors
US20180223372A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors
AU2015214264A1 (en) Mutant Smoothened and methods of using the same
JP7599716B2 (ja) がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化
WO2017095918A2 (en) Methods for treating cancer using rspo3 antagonists
WO2016201199A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors
HK1183435B (zh) 捲曲蛋白結合藥劑及其應用
HK1181401A (en) Frizzled-binding agents and uses thereof
AU2013206613A1 (en) Identification of tumor-associated antigens for diagnosis and therapy